 |
||||||||
 |
|
 |
 |
 |
 |
 |
|
|
Active Portfolio - EuropeA B C D E F G H I J K L M N O P Q R S T U V W X Y Z USA HISTORY PUBLIC |
|
|
7TM Pharma A/S (Denmark) focuses on the discovery and development of
peptides and small molecules for obesity, based on core expertise in seven
transmembrane receptors and disease biology. http://www.7tm.com/ |
|
Bicycle Therapeutics Limited (UK) is developing a novel technology for the creation of a new generation of biotherapeutics which combine the desirable features of small molecules and biopharmaceuticals. http://www.bicycletherapeutics.com/ |
|
f-star Biotechnologische Forschungs-und Entwicklungsges.m.b.H. (Austria and UK) is developing novel, differentiated therapeutic antibodies and antibody fragments using its Modular Antibody Technology. The technology enables the introduction of additional antigen binding sites into antibodies by engineering the non-CDR loops of constant or variable domains. http://www.f-star.com/ | 
|
Protaffin Biotechnologie AG (Austria) is developing a novel class of biopharmaceutical products that act by targeting cell-surface glycan structures for the treatment of inflammatory and oncology diseases. http://www.protaffin.com |
|
Syntaxin Ltd. (UK)uses its substantial knowledge of
microbial proteins and expertise in protein engineering to discover and
develop novel biopharmaceuticals that block cell secretion in a variety of
cell types for the treatment of pain, nervous, respiratory and metabolic
diseases. http://www.syntaxin.com/ |